Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The challenges of clinical trials in fragile X syndrome.

Psychopharmacology - 1 Mar 2014

Jacquemont Sébastien, Berry-Kravis Elizabeth, Hagerman Randi, von Raison Florian, Gasparini Fabrizio, Apostol George, Ufer Mike, Des Portes Vincent, Gomez-Mancilla Baltazar

Abstract excerpt

RATIONALE: Advances in understanding the underlying mechanisms of conditions such as fragile X syndrome (FXS) and autism spectrum disorders have revealed heterogeneous populations. Recent trials of novel FXS therapies have highlighted several challenges including subpopulations with possibly differential therapeutic responses, the lack of specific outcome measures capturing the full range of improvements of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child Development Disorders, Pervasive
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fragile X Syndrome

Share to FMR1 gene

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 24173622
DOI: 10.1007/s00213-013-3289-0
PMCID: PMC3932172

Genes

FMR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The challenges of clinical trials in fragile X syndrome.PMID 24173622Read ↗

The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome.Semantic proximity Read ↗

Fragile X Syndrome: From Molecular Aspect to Clinical Treatment.Semantic proximity Read ↗

Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back.Semantic proximity Read ↗

Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.Semantic proximity Read ↗

Measuring Effectiveness of Treatments in Rare Disorders, Evidence from Clinical Trials in Fragile X SyndromeSemantic proximity Read ↗

Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence.Semantic proximity Read ↗

Fragile X syndrome: A review of clinical managementSemantic proximity Read ↗

Advances in the treatment of fragile X syndrome.Semantic proximity Read ↗

The quest for targeted therapy in fragile X syndrome.Semantic proximity Read ↗

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)Semantic proximity Read ↗

Fragile X syndrome: from targets to treatments.Semantic proximity Read ↗

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.